文献速递膀胱癌与上尿路尿路上皮癌

DaBlaCa-13研究:复发性Ta非肌层浸润性膀胱癌膀胱内丝裂霉素C化学消融随机对照试验的5年随访

DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-03-20

该随机对照试验纳入120例复发性Ta低级别或高级别非肌层浸润性膀胱癌且>1个乳头状肿瘤<2 cm的患者,1:1随机接受短期强化丝裂霉素C化学消融(2周内6次灌注)或标准TURBT/活检后辅助灌注,随访5年。结果显示化学消融组接受TURBT的患者更少(64% vs 89%,p=0.003),完全避免手术的患者更多(17% vs 0%,p=0.002),5年无复发生存率两组无统计学差异(14% vs 28%,p=0.3)。

要点

  • 化学消融减少复发性NMIBC患者手术需求,不损害长期肿瘤学结局
  • 5年RFS两组无显著差异(14% vs 28%,HR=1.32,95%CI 0.86-2.01)
  • 基线肿瘤数目较少者RFS更优(p=0.012)

核心结论

  • 化学消融减少复发性NMIBC患者的手术操作需求,且不损害长期肿瘤学结局。
  • 这些发现支持将化学消融作为选定患者的微创治疗选择进行整合。

研究设计与样本

  • 随机对照试验,2018至2024年纳入120例复发性Ta低级别或高级别NMIBC且>1个乳头状肿瘤<2 cm的患者,1:1随机分组,随访5年。

主要发现

  • 化学消融组接受TURBT的患者比例低于标准组(64% vs 89%,p=0.003)。
  • 化学消融组完全避免手术的患者比例高于标准组(17% vs 0%,p=0.002)。
  • 无应答者从TURBT转向门诊操作(p=0.029)。
  • 5年RFS两组分别为14%与28%(p=0.3),无统计学显著差异(HR=1.32,95%CI 0.86-2.01)。
  • 基线肿瘤数目较少的患者RFS更优(p=0.012)。

关键数值与推荐

  • 主要终点为操作次数(TURBT或活检/电灼)和无复发生存期(RFS)。
  • 化学消融方案为2周内6次丝裂霉素C灌注。

临床怎么用

  • 对于复发性Ta低级别或高级别NMIBC且肿瘤<2 cm的患者,可考虑短期强化丝裂霉素C化学消融作为微创替代方案。
  • 化学消融可减少TURBT需求,但需注意5年RFS两组无显著差异,长期肿瘤学结局未受损。

局限性

  • 基线高级别肿瘤数量较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Transurethral resection of bladder tumors (TURBT) remains the standard treatment for non-muscle-invasive bladder cancer (NMIBC) but is associated with procedural risks and health care burden. Chemoresection using intravesical mitomycin C (MMC) has emerged as a minimally invasive alternative. This randomized controlled trial presents 5-yr follow-up data evaluating long-term outcomes of MMC chemoresection versus standard surgical management in patients with intermediate-risk NMIBC. METHODS: From 2018 to 2024, 120 patients with recurrent Ta low-grade or high-grade NMIBC and >1 papillary tumor <2 cm were randomized 1:1 to receive either short-term, intensive chemoresection (6 MMC instillations over 2 wk) or standard care with TURBT/biopsy followed by adjuvant instillations with a 5-yr follow-up. Primary end points were the number of procedures (TURBT or biopsy/fulguration) and recurrence-free survival (RFS). KEY FINDINGS AND LIMITATIONS: Fewer patients in the intervention group underwent TURBT (64% vs 89%, p = 0.003), and more patients avoided procedures entirely (17% vs 0%, p = 0.002). Nonresponders shifted from TURBT to office procedures (p = 0.029). At 5 yr, RFS was 14% vs 28% (p = 0.3), with no statistically significant between-group difference (hazard ratio = 1.32, 95% confidence interval 0.86-2.01). Patients with fewer baseline tumors had better RFS (p = 0.012). Findings are limited by a few high-grade tumors at baseline. CONCLUSIONS AND CLINICAL IMPLICATIONS: Chemoresection reduces the need for surgical procedures in patients with recurrent NMIBC without compromising long-term oncological outcomes. These findings support its integration as a less-invasive treatment option in selected patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Klingenberg S, Lindgren MS, Jakobsen JK, et al. DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2026. PMID: 41864769. doi:10.1016/j.euo.2026.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。